tetano
Editor, Senior Moderator
PLoS One. 2015 Apr 7;10(4):e0121590. doi: 10.1371/journal.pone.0121590. eCollection 2015.
[h=1]Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.[/h] de Oliveira JT[SUP]1[/SUP], Santos AL[SUP]2[/SUP], Gomes C[SUP]2[/SUP], Barros R[SUP]2[/SUP], Ribeiro C[SUP]2[/SUP], Mendes N[SUP]2[/SUP], de Matos AJ[SUP]3[/SUP], Vasconcelos MH[SUP]4[/SUP], Oliveira MJ[SUP]5[/SUP], Reis CA[SUP]6[/SUP], G?rtner F[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Oseltamivir phosphate is a widely used anti-influenza sialidase inhibitor. Sialylation, governed by sialyltransferases and sialidases, is strongly implicated in the oncogenesis and progression of breast cancer. In this study we evaluated the biological behavior of canine mammary tumor cells upon oseltamivir phosphate treatment (a sialidase inhibitor) in vitro and in vivo. Our in vitro results showed that oseltamivir phosphate impairs sialidase activity leading to increased sialylation in CMA07 and CMT-U27 canine mammary cancer cells. Surprisingly, oseltamivir phosphate stimulated, CMT-U27 cell migration and invasion capacity in vitro, in a dose-dependent manner. CMT-U27 tumors xenograft of oseltamivir phosphate-treated nude mice showed increased sialylation, namely α2,6 terminal structures and SLe(x) expression. Remarkably, a trend towards increased lung metastases was observed in oseltamivir phosphate-treated nude mice. Taken together, our findings revealed that oseltamivir impairs canine mammary cancer cell sialidase activity, altering the sialylation pattern of canine mammary tumors, and leading, surprisingly, to in vitro and in vivo increased mammary tumor aggressiveness.
PMID: 25850034 [PubMed - in process] Free full text
[h=1]Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.[/h] de Oliveira JT[SUP]1[/SUP], Santos AL[SUP]2[/SUP], Gomes C[SUP]2[/SUP], Barros R[SUP]2[/SUP], Ribeiro C[SUP]2[/SUP], Mendes N[SUP]2[/SUP], de Matos AJ[SUP]3[/SUP], Vasconcelos MH[SUP]4[/SUP], Oliveira MJ[SUP]5[/SUP], Reis CA[SUP]6[/SUP], G?rtner F[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Oseltamivir phosphate is a widely used anti-influenza sialidase inhibitor. Sialylation, governed by sialyltransferases and sialidases, is strongly implicated in the oncogenesis and progression of breast cancer. In this study we evaluated the biological behavior of canine mammary tumor cells upon oseltamivir phosphate treatment (a sialidase inhibitor) in vitro and in vivo. Our in vitro results showed that oseltamivir phosphate impairs sialidase activity leading to increased sialylation in CMA07 and CMT-U27 canine mammary cancer cells. Surprisingly, oseltamivir phosphate stimulated, CMT-U27 cell migration and invasion capacity in vitro, in a dose-dependent manner. CMT-U27 tumors xenograft of oseltamivir phosphate-treated nude mice showed increased sialylation, namely α2,6 terminal structures and SLe(x) expression. Remarkably, a trend towards increased lung metastases was observed in oseltamivir phosphate-treated nude mice. Taken together, our findings revealed that oseltamivir impairs canine mammary cancer cell sialidase activity, altering the sialylation pattern of canine mammary tumors, and leading, surprisingly, to in vitro and in vivo increased mammary tumor aggressiveness.
PMID: 25850034 [PubMed - in process] Free full text